Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 8/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LGMN | Q99538 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16695566 | 0.88 | NOTUM (0.51) | NOTUM | |
| SCHEMBL16684841 | 0.87 | IRAK4 (0.40) | MAPTPDK2NOTUMALDH1A1 | |
| SCHEMBL16695101 | 0.87 | IRAK4 (0.40) | MAPTPDK2NOTUMALDH1A1 | |
| SCHEMBL16695388 | 0.79 | NOTUM (0.51) | GHSRNOTUM | |
| SCHEMBL16695084 | 0.78 | GHSR (0.41) | MAPTPDK2GHSRNOTUMMEN1 | |
| SCHEMBL16695411 | 0.77 | MAPT (0.47) | MAPTPDK2PDE3BPDE3ANOTUM | |
| SCHEMBL22434593 | 0.71 | MAPT (0.57) | MAPTPDK2PDE3BPDE3ANOTUM | |
| SCHEMBL20887605 | 0.71 | MAPT (0.57) | MAPTPDK2PDE3BPDE3ANOTUM | |
| SCHEMBL20887690 | 0.71 | MAPT (0.57) | MAPTPDE3BPDE3ANOTUMHSD17B10 | |
| SCHEMBL19904630 | 0.71 | MAPT (0.57) | MAPTPDE3BPDE3ANOTUMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | MAPT 3882/4885PDK2 1020/4885GHSR 616/4885 |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, UGCG, GBA2 | MAPT 3882/4885PDK2 1020/4885GHSR 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.